2.5. DSF/Cu Improves the Response of BRAFV600E-Mutated Thyroid Cancer Cells to PLX4032 by Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Signaling Pathways. This evidence concerns the gene AKT1 and thyroid gland carcinoma.